uveal melanoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18 years and above, gender not limited, single eye disease not limited; 2. Clinical, pathological, or cytological diagnosis of uveal melanoma; 3. The distance between the posterior edge of the tumor and the optic disc is at least 3mm; No extraocular invasion; 4. When receiving this treatment, the maximum diameter of the tumor base is <= 19mm and the thickness is <= 10mm; 5. Voluntarily participate in this clinical trial and sign an informed consent form; 6. Willing to follow up and able to conduct follow-up according to the prescribed time;
Exclusion criteria
Exclusion criteria: 1. Exclusion of compliance: inability to comply with the study or belief by the researcher that they are unable to complete the study; 2. Patients with cranial diseases who cannot tolerate the side effects of radiation therapy; 3. Patients with systemic basic diseases that may seriously affect treatment, evaluation or compliance with the research scheme, including heart failure, respiratory failure, neurological or mental diseases (including alcohol or drug abuse), blood system diseases (coagulation dysfunction), immune system diseases (such as AIDS), infectious diseases (such as syphilis), malignant tumors or organ transplantation; 4. Patients with orbital deformities, a history of eye trauma, acute stage intraocular inflammation such as uveitis and keratitis, who are not suitable for periocular, retroocular or general anesthesia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Enucleation rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Recurrence rate;metastasis rate;median overall survival;Tumor control rate;Incidence of complications;Visual impairment rate;Effective visual acuity preservation rate; | — |
Countries
China
Contacts
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine